Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at Oppenheimer Holdings lowered their Q2 2017 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a report released on Thursday. Oppenheimer Holdings analyst D. Archila now expects that the biopharmaceutical company will post earnings of ($0.27) per share for the quarter, down from their prior forecast of ($0.25). Oppenheimer Holdings currently has a “Outperform” rating and a $21.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ FY2017 earnings at ($0.77) EPS.
VNDA has been the topic of a number of other research reports. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, June 7th. Jefferies Group LLC restated a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Finally, HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research note on Friday, May 26th. They issued a “buy” rating and a $18.00 target price on the stock. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $21.22.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/08/05/equities-analysts-issue-forecasts-for-vanda-pharmaceuticals-inc-s-q2-2017-earnings-vnda-updated-updated.html.
Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.35 on Monday. The company’s market cap is $728.43 million. Vanda Pharmaceuticals has a 12-month low of $10.81 and a 12-month high of $18.00. The stock’s 50 day moving average is $15.25 and its 200-day moving average is $14.52.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.04. The business had revenue of $37.42 million for the quarter, compared to the consensus estimate of $38.35 million. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%.
A number of large investors have recently added to or reduced their stakes in the company. Virginia Retirement Systems ET AL acquired a new stake in Vanda Pharmaceuticals during the first quarter valued at $193,000. Capital Fund Management S.A. acquired a new stake in Vanda Pharmaceuticals during the first quarter valued at $195,000. Dynamic Technology Lab Private Ltd acquired a new stake in Vanda Pharmaceuticals during the first quarter valued at $196,000. AQR Capital Management LLC acquired a new stake in Vanda Pharmaceuticals during the fourth quarter valued at $223,000. Finally, Algert Global LLC raised its stake in Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares during the period. Hedge funds and other institutional investors own 92.51% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.